DDInter107 DDInter1435
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors. In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or. Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eplerenone
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Polatuzumab vedotin
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delafloxacin
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Isavuconazonium
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Abemaciclib
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Eplerenone
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Apalutamide may lead to a major life threatening interaction when taken with Isavuconazonium
Apalutamide may lead to a major life threatening interaction when taken with Abemaciclib